Caplin Point Shares Fall 3% After US FDA Form 483

Caplin Point Laboratories shares fell nearly 3% on August 24 after a US FDA Form 483 cited 10 procedural observations at its Gummidipoondi facility. Caplin Point Laboratories

shares came under pressure on August 24, 2026, falling nearly 3% in morning trade after the company disclosed that its Caplin Steriles facility at Gummidipoondi had received a Form 483 from the US Food and Drug Administration (US FDA). The regulator conducted an unannounced inspection of the injectable and ophthalmic manufacturing facility between August 13 and 21. At the conclusion of the inspection, the US FDA issued a Form 483 containing 10 observations. Importantly, Caplin Point said the observations are procedural in nature and do not relate to data integrity. The company also stated that none of the observations were repeat observations. Despite Monday’s decline, the stock’s broader performance remains strong. Caplin Point Laboratories shares have gained more than 42% so far in calendar year 2026. The stock touched a fresh all-time high of ₹2,699 in July and is currently trading around 7% below that peak. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.